This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Vaccitech Completes $168M Series B Financing to Advance 3 Clinical Programs Through Phase 2 Results

Vaccitech Completes $168M Series B Financing to Advance 3 Clinical Programs Through Phase 2 Results

17 Mar 2021

Oxford, UK – Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares. The Series B... Read more

Immunometabolism company Sitryx expands into new space at TOSP

Immunometabolism company Sitryx expands into new space at TOSP

08 Mar 2021

Second occupier for Bellhouse Building at The Oxford Science Park Oxford, UK, March 8 2021 – Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics in inflammatory diseases and immuno-oncology, announces that it has expanded into new premises in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. Sitryx has developed... Read more

Exscientia completes $100 million Series C financing round with BlackRock funds

Exscientia completes $100 million Series C financing round with BlackRock funds

04 Mar 2021

Proceeds to further accelerate AI drug discovery platform and pipeline Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $100 million in funding. This new... Read more

WuXi AppTec Completes Acquisition of OXGENE to Strengthen Cell & Gene Therapy Service Offerings

WuXi AppTec Completes Acquisition of OXGENE to Strengthen Cell & Gene Therapy Service Offerings

02 Mar 2021

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers PHILADELPHIA and OXFORD, March 2, 2021 – WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract... Read more

Oxular raises $37 million – Led by specialist life sciences investor, Forbion

Oxular raises $37 million – Led by specialist life sciences investor, Forbion

01 Mar 2021

Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline OXFORD, UK, 1 March 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) financing led by Forbion. Proceeds will fund planned... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More